Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Concerned about...

    Concerned about Oxytocin misuse, CDSCO to outline regulatory control

    Written by supriya kashyap kashyap Published On 2017-09-28T16:41:54+05:30  |  Updated On 28 Sept 2017 4:41 PM IST
    Concerned about Oxytocin misuse, CDSCO to outline regulatory control

    New Delhi: Concerned about Oxytocin misuse, CDSCO is now going to ensure Strict Regulatory control over Manufacture, sale, and distribution of oxytocin and to curb its misuse. For the same district level, special task Force in each District of each State will be made to ensure that no Prohibited/regulated drug including Oxytocin


    CDSCO received a letter from Ministry of Health and Family Welfare stating that the following measures are to be taken in order to comply the directions of the Hon'ble High court, Himachal Pradesh, namely




    1. Constitution of a special task Force in each District of each State to ensure that no Prohibited/regulated drug including Oxytocin is freely available in each District in open market, save and accept in the manner prescribed.

    2. Concerned State Drug Controllers of the States where Licenses for manufacturing of Oxytocin have been issued shall examine the Licenses of all existing manufacturers of Oxytocin to ensure that the same have been issued strictly in accordance with Drugs and Cosmetics Act, 1940 and Rules 1945 and that the manufactures mandatorily comply with all the conditions of Drugs and Cosmetics Act, 1940 and Rules 1945, frame thereunder. Immediate appropriate actions as per the statutory provisions may be taken wherever violations of the rules are found.

    3. The State Drug Controller shall place on their respective websites by 10th of each month details of licenses issued to various manufacturers along with the monthly statement of production and sales of Oxytocin with complete particulars and details made by the manufacturers. The manufacturers of Oxytocin shall, in turn, submit these details in advance so as to reach the office of Drug Controller by 7th of every month.

    4. The wholesalers and retailers of all prohibited scheduled drugs including Oxytocin shall maintain records, as required under the law and the same shall be produced for inspection after every quarter before officer specifically deployed for this purpose by Drug Controller.

    5. CDSCO may take appropriate steps of undertaking IEC activities for sensitizing the public about ill-effects of Oxytocin both on the humans and the animals specially mulching cattle's, and about penal provisions for abuse/misuse of Oxytocin.


    Below is the attachment for the same.




    [pdf-embedder url="http://business.medicaldialogues.in/wp-content/uploads/2017/09/Oxytocin-notice.pdf"]
    CDSCODirectorate General of Health ServicesinspectionlicensesmanufacturesmanufacturingMinistry of Health and Family WelfareMisuseOxytocinregulatory controlscheduled drugsState Drug Controller

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok